Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent

Nuclear Medicine and Biology

Volumn 23, Issue 4, 1996, Pages 449-458

  Zalutsky, Michael R ^a   Archer, Gary E ^a   Garg, Pradeep K ^a   Batra, Surinder K ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chimeric antibody; Glioma; Monoclonal antibody; Radioiodination

Indexed keywords

IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6; TENASCIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NUDE MOUSE; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

EID: 0030152968     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00021-2     Document Type: Article

References (40)

1. 2 - A preliminary report. J. Neurooncol. 24, 109-122.
2. 2. Bourdon M. A., Coleman R. E., Blasberg R. G., Groothuis D. R. and Bigner D. D. (1984) Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res. 4, 133-140.
3. 3. Bourdon M. A., Wikstrand C. J., Furthmayr H., Matthews T. J. and Bigner D. D. (1983) Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 43, 2796-2805.
4. 4. Brown B. A., Davis G. L., Saltzgaber-Muller J., Simon P., Ho M.-K., Shaw P. S., Stone B. A., Sands H. and Moore G. P. (1987) Tumor-specific genetically engineered murine/human chimeric monoclonal antibody. Cancer Res. 47, 3577-3583.
5. 5. Buchsbaum D. J., Brubaker P. G., Hanna D. E., Glatfelter A. A., Terry V. H., Guilbault D. M. and Steplewski, Z. (1990) Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies. Cancer Res. (Suppl.) 50, 993s-999s.
6. 131I-labeled monoclonal antibody 17-1A treatment and external beam irradiation on the growth of LS174T human colon carcinoma xenografts. Int. J. Radiat. Oncol. Biol. Phys. 18, 1033-1041.
7. 7. Colcher D., Milenic D., Roselli M., Raubitschek A., Yarranton G., King D., Adair J., Whittle N., Bodmer M. and Schlom J. (1989) Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 49, 1738-1745.
8. 8. Garg P. K., Archer G. E. Jr., Bigner D. D. and Zalutsky M. R. (1989) Synthesis of radioiodinated N-succinimidyl iodobenzoate: Optimization for use in antibody labeling. Appl. Rad. Isotop. 40, 485-490.
9. 2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods. Bioconjugate Chem. 6, 493-501.
10. 10. Gillies S. D. and Wesolowski J. S. (1990) Antigen binding and biological activities of engineered mutant chimeric antibodies with human rumor specificities. Hum. Antibodies Hybridomas 1, 45-52.
11. 11. Goodman G. E., Hellstrom I., Yelton D. E., Murray J. L., O'Hara S., Meaker E., Zeigler L., Palazollo P., Nicaise C., Usakewicz J. and Hellstrom K. E. (1993) Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer. Immunol. Immunother. 36, 267-273.
12. 12. Hardman N., Gill L. L., De Winter R. F. J., Wagner K., Hollis M., Businger F., Ammaturo D., Buchegger F., Mach J-P. and Heusser C. (1989) Generation of a recombinant mouse-human chimeric monoclonal antibody directed against human carcinoembryonic antigen. Int. J. Cancer 44, 424-433.
13. 13. He X., Archer G. E., Wikstrand C. J., Morrison S. L., Zalutsky M. R., Bigner D. D. and Batra S. K. (1994) Generation and chatacterization of a mouse/human chimeric antibody directed against extracellular matix protein tenascin. J. Neuroimmunol. 52, 127-137.
14. 14. Horgan C., Brown K. and Pincus S. H. (1993) Studies on antigen binding by intact and hinge-deleted chimeric antibodies. J. Immunol. 150, 5400-5407.
15. 15. Howeedy A. A., Virtanen I., Laitinen L., Gould N. S., Koukoulis G. K. and Gould V. E. (1990) Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab. Invest. 63, 798-806.
16. 1). Cancer Res. 51, 181-189.
17. 17. Jeong J. M., Kinuya S., Paik C. H., Saga T., Sood V. K., Carrasquillo J. A., Neumann R. D. and Reynolds J. C. (1994) Application of high affinity binding concept to radiolabel avidin with Tc-99m labeled biotin and the effect of pI on biodistribution. Nucl. Med. Biol. 21, 935-940.
18. 18. Khaw B., Klibanov A., O'Donnell S. M., Saito T., Nossiff N., Slinkin M. A., Newell J. B., Strauss H. W. and Torchilin V. P. (1991) Gamma imaging with negatively charge-modified monoclonal antibody: Modification with synthetic polymers. J. Nucl. Med. 32, 1742-1751.
19. 19. Lindmo T., Boven E., Cuttitta F., Fedoroko J. and Bunn P. A. Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89.
20. 20. Mackie E. J., Chiquet-Ehrismann R., Pearson C. A., Inaguma Y., Taya K., Kawarada Y. and Sakakura T. (1987) Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc. Natl. Acad. Sci. USA 84, 4621-4625.
21. 21. Marin L. A., Smith C. E., Langston M. Y., Quashie D. and Dillehay L. E. (1991) Response of glioblastoma cell lines to low dose rate irradiation. Radiat. Oncol. Biol. Phys. 21, 397-402.
22. 22. Means, G. E. and Feeney, R. E. (1971) Chemical Modification of Proteins, pp. 175-182. Holden-Day, San Francisco.
23. 23. Molthoff C. F., Buist M. R., Kenemans P., Pinedo H. M. and Boven E. (1992) Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J. Nucl. Med. 33, 2000-2005.
24. 24. Morelock M. M., Rothlein R., Bright S. M., Robinson M. K., Graham E. T., Sabo J. P., Owens R., King D. J., Norris S. H., Scher D. S., Wright J. L. and Adair J. R. (1994) Isotype choice for chimeric antibodies affects binding properties. J. Biol. Chem. 269, 13048-13055.
25. 25. Morrison S. L. and Oi V. T. (1984) Transfer and expression of immunoglobulin genes. Annu. Rev. Immunol. 2, 239-256.
26. 26. Murphy-Ullrich J. E., Lightner V. A., Aukhil I., Yan Y. Z., Erickson H. P. and Höök M. (1991) Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J. Cell Biol. 115, 1127-1136.
27. 27. Novak-Hofer I., Amstutz H. P., Haldemann A., Blaser K., Morgenthaler J. J., Blauenstein P. and Schubiger P. A. (1992) Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7. J. Nucl. Med. 33, 231-236.
28. 28. Saga T., Endo K., Koizumi M., Kawamura Y., Watanabe Y., Konishi J., Ueda R., Nishimura Y., Yokoyama M. and Watanabe T. (1989) In vitro and in vivo properties of human/mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. J. Nucl. Med. 31, 1077-1083.
29. 29. Sahagan B. G., Dorai H., Saltzaber-Muller J., Toneguzzo F., Guindon C. A., Lilly S. P., McDonald K. W., Morrisey D. V., Stone B. A., Davis G. L., McIntosh P. K. and Moore G. P. (1986) A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen. J. Immunol. 137, 1066-1074.
30. 30. Schuster J. M., Garg P. K., Bigner D. D. and Zalutsky, M. R. (1991) Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. Cancer Res. 51, 4164-4169.
31. 31. Shaw D. R., Khazaeli M. B. and LoBuglio A. F. (1988) Mouse/human chimeric antibodies to a tumor-associated antigen: Biologic activity of the four human IgG subclasses. J. Natl. Cancer Inst. 80, 1553-1559.
32. 32. Shin S.-U. (1991) Chimeric antibody: Potential applications for drug delivery and immunotherapy. Biotherapy 3, 43-53.
33. 2 fragments conjugated with chelating polymers: Influence of conjugate electron charge on tumor uptake and blood clearance. Nucl. Med. Biol. 20, 443-452.
34. 34. Sun L. K., Curtis P., Rakowice-Szulczynska E., Ghrayeb J., Chang N., Morrison S. L. and Koprowski H. (1987) Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc. Natl. Acad. Sci USA 84, 214-218.
35. 35. Tjandra J. J., Ramadi L. and McKenzie I. F. (1990) Development of human anti-murine antibody (HAMA) response in patients. Immunol. Cell Biol. 68, 367-376.
36. 36. Triguero D., Buciak J. B. and Pardridge W. M. (1991) Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J. Pharmacol. Exper. Ther. 258, 186-192.
37. 37. Triguero D., Buciak J. B., Yang J. and Pardridge W. M. (1989) Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein. Proc. Natl. Acad. Sci. USA 86, 4761-4765.
38. 38. Weiden P. L., Breitz H. B., Seiler C. A., Bjorn M. J., Ratliff B. A., Mallett R., Beaumier P. L., Appelbaum J. W., Fritzberg A. R. and Salk D. (1993) Rhenium-186-labeled chimeric antibody NR-LU-13: Phamacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10. J. Nucl. Med. 34, 2111-2119.
39. 39. Wikstrand C. J., McLendon R. E., Carrel S., Kemshead J. T., Mach J.-P., Coakham H. B., de Tribolet N., Bullard D. E., Zalutsky M. R. and Bigner D. D. (1987) Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. J. Neuroimmunol. 15, 37-56.
40. 40. Zalutsky M. R., Noska M. A., Colapinto E. V., Garg P. K. and Bigner D. D. (1989) Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res. 49, 5543-5549.